Abstract
Exertional dyspnoea associated with oxygen desaturation is a common feature of the early stages of fibrotic interstitial lung diseases (f-ILD), and ambulatory oxygen is the only intervention shown to acutely improve exercise capacity in these patients, with positive effects on quality of life. Nevertheless, its use remains controversial, with a marked mismatch between expectations and real-world experience among both patients and clinicians, poor acceptability, and a tendency towards withholding oxygen treatment until resting hypoxaemia develops. This review discusses the physiological mechanisms underlying the effects of ambulatory oxygen, the strengths and limitations of currently available oxygen delivery systems, and the factors influencing its acceptability according to the Theoretical Framework of Acceptability. It distinguishes between efficacy, real-world effectiveness, and acceptability as complementary determinants of clinical benefit, and proposes a practical framework for integrating these dimensions into the process of Shared Decision Making. As antifibrotic therapies prolong the period during which patients remain in the stage of isolated exertional hypoxaemia, the opportunity to preserve autonomy and quality of life with ambulatory oxygen may increase, highlighting the clinical relevance of appropriate assessment and use of ambulatory oxygen in this population.